Targeted delivery of nanoparticles for the treatment of lung diseases
S Azarmi, WH Roa, R Löbenberg - Advanced drug delivery reviews, 2008 - Elsevier
Targeted delivery of drug molecules to organs or special sites is one of the most challenging
research areas in pharmaceutical sciences. By developing colloidal delivery systems such …
research areas in pharmaceutical sciences. By developing colloidal delivery systems such …
Current perspectives in dissolution testing of conventional and novel dosage forms
S Azarmi, W Roa, R Löbenberg - International Journal of pharmaceutics, 2007 - Elsevier
The purpose of this article is to review USP and non-pharmacopeial dissolution testing methods
for conventional and novel pharmaceutical dosage forms and give an insight to possible …
for conventional and novel pharmaceutical dosage forms and give an insight to possible …
Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery—a review
…, R Löbenberg, T Ku, S Azarmi, W Roa… - Journal of …, 2007 - ingentaconnect.com
… Wilson Roa is a professor of oncology at the University of Alberta and a senior medical …
Roa contributes to scientific steering committees of research groups and consortiums, such …
Roa contributes to scientific steering committees of research groups and consortiums, such …
International atomic energy agency randomized phase III study of radiation therapy in elderly and/or frail patients with newly diagnosed glioblastoma multiforme
Purpose The optimal radiotherapy regimen for elderly and/or frail patients with newly
diagnosed glioblastoma remains to be established. This study compared two radiotherapy …
diagnosed glioblastoma remains to be established. This study compared two radiotherapy …
[HTML][HTML] Short-course radiation plus temozolomide in elderly patients with glioblastoma
…, R Nishikawa, JG Cairncross, W Roa… - … England Journal of …, 2017 - Mass Medical Soc
Background Glioblastoma is associated with a poor prognosis in the elderly. Survival has
been shown to increase among patients 70 years of age or younger when temozolomide …
been shown to increase among patients 70 years of age or younger when temozolomide …
Gold nanoparticle sensitize radiotherapy of prostate cancer cells by regulation of the cell cycle
W Roa, X Zhang, L Guo, A Shaw, X Hu, Y Xiong… - …, 2009 - iopscience.iop.org
Glucose-capped gold nanoparticles (Glu-GNPs) have been used to improve cellular targeting
and radio-sensitization. In this study, we explored the mechanism of Glu-GNP enhanced …
and radio-sensitization. In this study, we explored the mechanism of Glu-GNP enhanced …
Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial
W Roa, PMA Brasher, G Bauman, M Anthes… - Journal of clinical …, 2004 - ascopubs.org
Purpose To prospectively compare standard radiation therapy (RT) with an abbreviated
course of RT in older patients with glioblastoma multiforme (GBM). Patients and Methods One …
course of RT in older patients with glioblastoma multiforme (GBM). Patients and Methods One …
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases
…, CHJ Terhaard, A Rao, J Suh, W Roa… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: This phase III randomized trial evaluated survival as well as neurologic and
neurocognitive function in patients with brain metastases from solid tumors receiving whole-brain …
neurocognitive function in patients with brain metastases from solid tumors receiving whole-brain …
Toxicity and outcome results of RTOG 9311: A phase I–II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non–small …
…, R Komaki, WH Roa, JK Ryu, W Bosch… - International Journal of …, 2005 - Elsevier
PURPOSE: To evaluate prospectively the acute and late morbidities from a multiinstitutional
three-dimensional radiotherapy dose-escalation study for inoperable non–small-cell lung …
three-dimensional radiotherapy dose-escalation study for inoperable non–small-cell lung …
[PDF][PDF] Randomized, double-blind, placebo-controlled trial of erythropoietin in non–small-cell lung cancer with disease-related anemia
…, C Smith, B Szechtman, W Roa… - Journal of Clinical …, 2007 - researchgate.net
Purpose Previous trials have suggested a quality-of-life (QOL) improvement for anemic
cancer patients treated with erythropoietin, but few used QOL as the primary outcome. We …
cancer patients treated with erythropoietin, but few used QOL as the primary outcome. We …